Experience-sharing interview: Managing a complicated case of lower urinary tract symptoms
At the recent launch of an exclusive guidebook on vasodilating β-blockers for the treatment of hypertension and chronic heart failure (HF), Professor Athanasios J. Manolis delivered a lecture on why nebivolol is different from the other agents in its class.
At the recent Alcon launch symposium of Systane® Hydration in Kuala Lumpur, three prominent speakers shared their experiences on the management of ocular dryness and highlighted the role of the new therapy.
At the launch of Caris Molecular Intelligence® in Malaysia, Dr Andrew Dean, Head of Oncology at the St John of God Subianco Hospital, Perth, shared with the audience on molecular profiling and its benefits, with a focus on the Caris Molecular Intelligence® service.
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, was associated with a reduced rate of disability progression in individuals with primary progressive multiple sclerosis (MS), based on findings of the phase III ORATORIO* trial.
At the Abbott-sponsored continuing medical education programme in commemorating the 25th anniversary of Duphaston® (dydrogesterone, Abbott) in Malaysia, Dr Raman Subramaniam and Dr Eeson Sinthamoney presented clinical updates in the management of threatened and recurrent miscarriages. Highlights of their presentations are summarized below.
At the recent Malaysian Osteoporosis Society 2016 Clinical Practice Guideline (CPG) Meeting held on the 8th of October 2016 at Ibis Styles Ipoh, Dr Hew Fen Lee and Professor Dr Chan Siew Pheng presented clinical guidance on the management of osteoporosis, and discussed whether the benefits of treatment outweigh the risks.
Recently, randomized controlled trials and guidelines have brought to light the benefits of extending the duration of H. pylori treatment. Below are summaries of guidelines and trials examining the regimens used to manage the infection.
At the Diabetes Asia 2016 Conference organized by the National Diabetes Institute, Professor Jean Claude Mbanya presented the case for why gliclazide modified release (MR; Diamicron® MR, Servier) should be the treatment of choice for early and aggressive control of type 2 diabetes (T2D).
At a recent dinner symposium, an expert from Belgium presented on the management of allergic rhinitis, with a particular focus on the use of oral H1-antihistamines and intranasal glucocorticosteroids.